Sanskriti Sasikumar1, Roberto Matta2, Renato P Munhoz1,3,4, Mateusz Zurowski5, Yu-Yan Poon3, Mojgan Hodaie4,6, Suneil K Kalia4,6, Andres M Lozano4,6, Alfonso Fasano1,3,4,7. 1. Division of Neurology University of Toronto Toronto Ontario Canada. 2. University of Cagliari Cagliari Italy. 3. Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Centre Toronto Western Hospital, UHN Toronto Ontario Canada. 4. Krembil Brain Institute Toronto Ontario Canada. 5. Toronto Western Hospital, Department of Psychiatry University of Toronto Toronto Ontario Canada. 6. Toronto Western Hospital, Division of Neurosurgery University of Toronto Toronto Ontario Canada. 7. Center for Advancing Neurotechnological Innovation to Application (CRANIA) Toronto Ontario Canada.
Abstract
BACKGROUND: Dopamine Dysregulation Syndrome (DDS) is an adverse non-motor complication of dopamine replacement therapy in Parkinson's disease. The current literature on this syndrome is limited, and it remains underdiagnosed and challenging to manage. OBJECTIVE: To assess the role of advanced therapies in the management of DDS. METHODS: We performed a retrospective chart review and identified patients who fit the inclusion criteria for DDS. They were classified according to risk factors that have been identified in the literature, motor and complication scores, intervention (medical or surgical) and outcome. Multivariate analyses were performed to analyze these characteristics. RESULTS: Twenty-seven patients were identified (23 males, mean age of onset: 49 ± 8.8 years). Average levodopa equivalent daily dose was 1916.7 ± 804 mg and a history of impulse control disorders, psychiatric illness, and substance abuse was present in 89%, 70% and 3.7% of the patients, respectively. Overall 81.5% of patients had symptom resolution at follow up, on average 4.8 ± 3.5 years after management, with medication only (7/9), levodopa-carbidopa intestinal gel (1/3), deep brain stimulation of subthalamic nucleus (10/13), or globus pallidus pars interna (2/2). Reduction of medications occurred with deep brain stimulation of subthalamic nucleus (P = 0.01) but was associated with a relapse in two patients. CONCLUSION: Although the small sample size of some subgroups limits our ability to draw meaningful conclusions, our results did not suggest superiority of a single treatment option. Advanced therapies including deep brain stimulation can be considered in patients with DDS refractory to conservative measures, but outcome is variable and relapse is possible.
BACKGROUND: Dopamine Dysregulation Syndrome (DDS) is an adverse non-motor complication of dopamine replacement therapy in Parkinson's disease. The current literature on this syndrome is limited, and it remains underdiagnosed and challenging to manage. OBJECTIVE: To assess the role of advanced therapies in the management of DDS. METHODS: We performed a retrospective chart review and identified patients who fit the inclusion criteria for DDS. They were classified according to risk factors that have been identified in the literature, motor and complication scores, intervention (medical or surgical) and outcome. Multivariate analyses were performed to analyze these characteristics. RESULTS: Twenty-seven patients were identified (23 males, mean age of onset: 49 ± 8.8 years). Average levodopa equivalent daily dose was 1916.7 ± 804 mg and a history of impulse control disorders, psychiatric illness, and substance abuse was present in 89%, 70% and 3.7% of the patients, respectively. Overall 81.5% of patients had symptom resolution at follow up, on average 4.8 ± 3.5 years after management, with medication only (7/9), levodopa-carbidopa intestinal gel (1/3), deep brain stimulation of subthalamic nucleus (10/13), or globus pallidus pars interna (2/2). Reduction of medications occurred with deep brain stimulation of subthalamic nucleus (P = 0.01) but was associated with a relapse in two patients. CONCLUSION: Although the small sample size of some subgroups limits our ability to draw meaningful conclusions, our results did not suggest superiority of a single treatment option. Advanced therapies including deep brain stimulation can be considered in patients with DDS refractory to conservative measures, but outcome is variable and relapse is possible.
Authors: María José Catalán; Eduardo de Pablo-Fernández; Clara Villanueva; Servando Fernández-Diez; Teresa Lapeña-Montero; Rocío García-Ramos; Eva López-Valdés Journal: Mov Disord Date: 2013-10-10 Impact factor: 10.338
Authors: Pedro Barbosa; Bimali Hapuarachchi; Atbin Djamshidian; Kate Strand; Andrew J Lees; Rohan de Silva; Janice L Holton; Thomas T Warner Journal: Brain Date: 2019-11-01 Impact factor: 13.501